“Our goal at RoosterBio is to simplify the scale-up of hMSC manufacturing processes, compress development timelines, and accelerate speed to market." - Jon A. Rowley, PhD, RoosterBio's CPO
FREDERICK, Md. (PRWEB) January 25, 2019
Today, RoosterBio Inc. announces the launch of RoosterBank™-hBM-100M-XF, a closed-system xeno-free (XF) working cell bank for rapid scale-up. This single-use bag product format enables streamlined, scalable hMSC-based manufacturing by providing a cell solution containing 100 million bone marrow-derived hMSCs (with industry-leading functional characterization) in a weldable cryopreservation bag that efficiently and economically reaches billions of cells. Supporting RoosterBio’s development grade (RUO) product portfolio, RoosterBank-XF provides researchers and product developers with a standardized, bioreactor-ready, option to scale-up or scale-out all while utilizing translation-friendly, XF starting materials.
RoosterBio remains laser focused on their revolutionary approach to change the way therapies and devices that require living cells are commercialized and moves one step closer to blasting open the most significant bottleneck in the Regenerative Medicine industry. This effort in-part stems from an innovation catalyst – TEDCO managed and state-funded Maryland Stem Cell Research Fund (MSCRF) Commercialization Program – to develop scale-up cell bank manufacturing. The program helped realize a commercially-viable stem cell manufacturing process for closed-system (high-volume) working cell banks. Effectively, RoosterBio continued to drive down the cost per million cells with this disruptive product format.
Founder & Chief Product Officer, Jon A. Rowley, PhD said, “Our goal at RoosterBio is to simplify the scale-up of hMSC manufacturing processes, compress development timelines, and accelerate speed to market. Today’s technology programs and tomorrow’s Regenerative Medicine products require scalable lot sizes of high-quality cells to quickly move through clinical development. This innovative product format, which we were lucky to have State support in developing, is instantly impacting the development of some of the most promising Regenerative Medicine programs around the globe.”
About RoosterBio Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult hMSCs paired with highly engineered bioprocess media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).